Menu
Not yet recruiting NCT07494487

Reliability of Community Ambulation Ability, Fall Risk, and Dynamic Visual Acuity Assessments in Stroke

Observational Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Stroke. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Reliability of Community Ambulation Assessments, Taiwan Chinese Version of Falls Efficacy Scale, and Dynamic Visual Acuity Test in Individuals With Chronic Stroke

Overview

Nearly half of individuals with stroke experience limitations in community ambulation, and 35.7% of community-dwelling stroke survivors experienced falls while walking, indicating that falls are common during routine daily activities in community settings. Patla (1999) proposed that community mobility is influenced by eight factors: ambient conditions, terrain characteristics, external physical load, attentional demands, postural transitions, traffic level, time constraints, and walking distance. This framework suggests that community ambulation requires consideration of multiple physiological domains as well as environmental factors. However, current assessments of community ambulation primarily rely on indoor walking speed as an indicator, which may be insufficient to fully evaluate patients' community ambulation ability. Previous studies have not yet established the reliability of community ambulation assessments such as the Walking Ability Questionnaire, community walking speed, and the Falls Efficacy Scale (Taiwan Chinese version)-in individuals with chronic stroke. Additionally, stroke survivors often demonstrate insufficient integration of vestibular information, which may affect gait performance through impaired dynamic visual acuity. Therefore, this study aims to investigate the reliability of community ambulation assessments and dynamic visual acuity testing in individuals with chronic stroke.

Primary outcome measures

  • Walking Ability Questionnaire [Time frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session]
  • Community Walking Speed [Time frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session]
  • Taiwan Chinese Version of the Falls Efficacy Scale [Time frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session]
  • Dynamic Visual Acuity Test [Time frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session]

Eligibility criteria

Inclusion criteria

  • Diagnosis of First-occurrenced stroke
  • ≥ 6 months after stroke
  • Ability to walk at least 400 meters with or without the use of a walking assistive device
  • Mini-Mental State Examination score ≥ 24
  • Age between 18 and 80 years

Exclusion criteria

  • Other neurological or musculoskeletal conditions affected postural stability
  • Presence of dizziness or vertigo
  • Presence of conditions affecting cervical blood flow or limiting cervical range of motion
  • Visual impairment
  • Unstable cardiac status or uncontrolled hypertension

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Taiwan · 1 center
  • Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung Uni — Taipei

Identifiers

NCT: NCT07494487 · NYCU114245AF1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗